Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Urelumab, a fully human, non‐ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T‐cell and natural killer‐cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B‐cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383599/
https://www.ncbi.nlm.nih.gov/pubmed/32052473
http://dx.doi.org/10.1002/ajh.25757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383599/
https://www.ncbi.nlm.nih.gov/pubmed/32052473
http://dx.doi.org/10.1002/ajh.25757

Ejemplares similares